|Bid||1,387.80 x 0|
|Ask||1,388.20 x 0|
|Day's range||1,386.00 - 1,414.40|
|52-week range||1,190.80 - 1,528.80|
|Beta (5Y monthly)||0.38|
|PE ratio (TTM)||15.99|
|Forward dividend & yield||0.80 (5.66%)|
|Ex-dividend date||19 Aug 2021|
|1y target est||N/A|
Dr. Arthur Caplan, NYU Langone Health, Division of Medical Ethics at NYU School of Medicine, joins Yahoo Finance to discuss the latest on the coronavirus vaccines and booster shots.
23andMe CEO Anne Wojcicki joins 'Influencers with Andy Serwer' to discuss the politicization of medicine amid the COVID-19 pandemic.
Shares of Vir Biotechnology (NASDAQ: VIR) were sinking 18.1% for the week as of the market close on Thursday. Vir was pulled down by the overall stock market sell-off earlier this week. It's best to avoid making investment decisions based on analysts' downgrades (and upgrades, for that matter).